| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 324.9 | 115.4 |
| Stock-based compensation expense | 159.3 | 105.6 |
| Charges associated with convertible senior notes | 0 | 0 |
| Operating lease, impairment loss | 0.7 | - |
| Depreciation | 19.6 | 12.9 |
| Accretion of discount on available-for-sale debt securities, net | 10.7 | 8 |
| Impairment charges associated with leased properties | - | 0.7 |
| Amortization of intangible assets | 3 | 2 |
| Changes in fair values of equity investments | -6.7 | -37.3 |
| Deferred income taxes | 117.2 | -51.1 |
| Non-cash lease expense | 20.9 | 14.3 |
| Other | 0.7 | 0.5 |
| Accounts receivable | 248.9 | 116.6 |
| Inventory | 11.9 | -0.4 |
| Accounts payable and accrued liabilities | 83.7 | 27.9 |
| Income tax assets and liabilities | -54.3 | - |
| Other assets and liabilities, net | 16.6 | -25.5 |
| Cash flows from operating activities | 394.3 | 166.8 |
| Purchases of available-for-sale debt securities | 996.8 | 588.3 |
| Sales and maturities of available-for-sale debt securities | 821.7 | 596.7 |
| Capital expenditures | 36.4 | 23.2 |
| Cash flows from investing activities | -211.5 | -14.8 |
| Issuances of common stock under benefit plans | 92.1 | 46.5 |
| Repurchases of common stock | 167.7 | 167.7 |
| Payments to settle convertible senior notes | 0 | 0 |
| Cash flows from financing activities | -75.6 | -121.2 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0.2 |
| Change in cash, cash equivalents and restricted cash | 107.2 | 31 |
| Cash and cash equivalents at beginning of period | 241 | - |
| Cash and cash equivalents at end of period | 348.2 | - |
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)